After the Fifth Circuit Court of Appeals in the United States issued a temporary stay on Monday, R.J. Reynolds Vapor is allowed to continue selling its Vuse products in two mint flavors that had been subject to a marketing denial order (MDO).
Last Friday, the US Food and Drug Administration (FDA) rejected R.J. Reynolds' PMTA for its Vuse alternative pod mint 4.8% (nicotine content) G1 and Vuse alternative pod mint 4.8% G2 tobacco products.
As a result, Renault will be prohibited from selling or distributing these products in the United States, or else it will face enforcement action from the US Food and Drug Administration. However, the appellate court's ruling allows these products to continue being sold in the market.
A similar incident occurred. In October of last year, the US Food and Drug Administration issued a marketing denial order (MDO) against several mint-flavored soda products sold by Logic Technology Development. This was the first time the FDA had issued an MDO against mint products after undergoing scientific review.
After several days, Logic Corporation obtained a court order from the U.S. Third Circuit Court of Appeals to temporarily suspend the order.
Related reading:
British American Tobacco seeks to halt FDA's marketing ban on two Vuse e-cigarette products.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
